Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Like Ariad Pharmaceuticals, Inc. (ARIA) Despite the Failed Deal

Less than a week after reports that Baxalta Inc (NYSE:BXLTwanted to acquire Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), the discussions of a deal, might be over, although none of the two reports have been officially confirmed by either one of the companies. According to Bloomberg, citing people familiar with the matter, the negotiations failed because the parties could not agree on a price. The news has negatively affected Ariad’s stock on Wednesday, but it started recovering on Thursday, advancing by over 3%.

Baxalta’s stock has also jumped by almost 4% today, but in this case, the news about the deal with Ariad being off the table, has been positively received by investors. Baxalta, which was spun off from Baxter International Inc (NYSE:BAX) in July, is currently trying to fend off a $30-billion takeover by Shire PLC (ADR) (NASDAQ:SHPG), and the acquisition of Ariad was mostly seen as a move to prevent a deal with Shire. However, Baxalta considers that the current terms, undervalues it.

Biotech Stocks 9

The healthcare sector has seen a lot of mergers and acquisitions since the start of last year. The talks between companies such as Baxalta Inc (NYSE:BXLT), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Shire PLC (ADR) (NASDAQ:SHPG) are among the latest. Shire itself was subject of a failed takeover bid last year. These deals, aimed at refocusing firms, bolstering market shares and growth, or unlocking shareholder value, are usually  favored by smart money and hedge funds try to target these deals and often push for them to take place.

The general opinion is that hedge funds underperform the S&P 500 based on net returns. However, they pull in strong returns from their top small-cap ideas and invest a lot of their resources into analyzing these stocks. They simply don’t take large enough positions in them relative to their portfolios to generate strong overall returns because their large-cap picks underperform the market. We share the top 15 small-cap stocks favored by the best hedge fund managers every quarter and this strategy has managed to outperform the S&P 500 ETF (SPY) every year since it was launched in August 2012 and has returned 118% and has beat the market by more than 60 percentage points (read more details). Because of this, we know that collective hedge fund sentiment is valuable and can provide a lot of insight to retail investors.

With this in mind, let’s take a closer look at the latest hedge fund activity surrounding Ariad Pharmaceuticals.

According to the data from the latest round of 13F filings, hedge funds from our database are bullish on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). The number of investors with long positions declined to 31 from 38 during the second quarter, while the aggregate value of their holdings slid by 11% on the quarter to $401.61 million. However, these investors hold more than 25% of Ariad’s outstanding stock.

More specifically, Alex Denner’s healthcare-focused Sarissa Capital Management owns the largest stake in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), which contains 12.85 million shares worth about $106.27 million. David Costen Haley’s HBK Investments initiated a stake during the second quarter and reported 120,700 shares in its latest 13F. Dmitry Balyasny’s Balyasny Asset Management increased his take by 11% to 1,519,292 shares. However, Israel Englander’s Millennium Management reduced its stake by 60% to 673,253 shares.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!